• Clinical Trials - Hepatitis C (HCV)

    Study Objective Contact
    A Multi-Center, Randomized, Prospective Open- Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients [LCID Study Number: 2014-023] This purpose of this study is to test the safety of different doses of the investigational therapy Hepatitis C Immune Globulin (HCIG) when given to patients with Hepatitis-C (HCV) who undergo liver transplantation. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Comparative Assessment of Effectiveness of Antiviral Therapies in Hepatitis C (CMPASS) [LCID Study Number: 2012-075] The purpose of this study is to get a better understanding of how patients with chronic Hepatitis C (HCV) are treated and how their disease is managed in the “real world”. Understanding how well available treatments for HCV work and how well patients are able to tolerate the medications will help guide doctors on how best to treat patients in the future. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Impact of IL-28B Gene Polymorphism on Outcome of Patients Undergoing Liver Transplantation for Hepatitis C [LCID Study Number: 2012-073] The purpose of this study is to collect data on favorable donor-recipient pairing, grafts, genotypes and patient outcomes. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Fredric D. Gordon, MD.
    Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with or without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection [LCID Study Number: 2013-027] The purpose of this study is to see if 3 investigational drugs (ABT-450/r/ABT-267, and ABT-333) taken with or without ribavirin is safe and able to reduce the amount of hepatitis C virus in the blood of patients with Hepatitis C. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos.
    Testing for Hepatitis C in the Screening Colonoscopy Population [LCID Study Number: 2014-085] The purpose of this study is to help determine the efficacy of screening the outpatient colonoscopy population for asymptomatic cases of HCV infection in patients born between 1945 and 1965. This study will involve only a one-time visit to the laboratory for one blood specimen that will be tested for the presence or absence of the antibody to the Hepatitis C Virus. If an antibody is detected, the same blood sample will be used to test for the presence of the actual virus. If blood testing confirms the presence of Hepatitis C infection, the patient will be contacted to schedule an appointment in the Gastroenterology Department to discuss further care. Principal Investigator(s):
    Stephen C. Fabry, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Jeffrey P. Fiorenza.